Apogee Therapeutics Income Statement (2022-2026) | APGE

1Y3Y5Y7Y10YAll
Download Data
Income Statement Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & Cost
Interest income
Interest Income - Total (Quarter) -6.09M-10.31M-9.67M-8.68M-7.84M-7.14M-6.32M-8.73M
Interest expenses
Interest Expenses (Quarter) 6.68M1.32M30.18M115.69M0.05M0.10M76.08M0.04M57.20M43.93M216.17M268.16M
Interest Income - Net (Quarter) -121.78M-10.35M-9.77M-84.76M-7.88M-64.34M-50.25M-224.90M
Operating Items
Research & Development (Quarter) 1.45M9.88M12.21M8.46M13.95M17.07M28.95M28.72M33.21M45.71M60.23M46.39M55.70M54.18M58.44M60.82M67.30M
Selling, General & Administrative (Quarter) 0.37M0.62M1.89M4.20M4.94M7.24M8.20M9.46M10.92M12.97M15.65M16.71M17.46M17.10M19.61M21.95M24.34M
Other Operating Expenses (Quarter) 4.36M
Operating Expenses (Quarter) 96.00M
Operating Income (Quarter) -96.00M
EBIT (Quarter) -96.00M
Non-operating items
Interest & Investment Income (Quarter) 11.81M
Other Non Operating Income (Quarter) 10.23M
Net income details
EBT (Quarter) -85.78M
Tax Provisions (Quarter) 0.08M
Profit After Tax (Quarter) -85.85M
Income from Continuing Operations (Quarter) -85.85M
Consolidated Net Income (Quarter) -85.85M
Income towards Parent Company (Quarter) -85.85M
Net Income towards Common Stockholders (Quarter) -85.85M
Additional items
EPS (Basic) (Quarter) -1.14
EPS (Diluted) (Quarter) -1.14
Shares Outstanding (Quarter) 75.44M
Shares Outstanding (Diluted) (Quarter) 75.44M
Shares Outstanding (Entity) (Quarter) 75.61M
EBITDA (Quarter) -96.00M